AUA 2013 - Poster: Does adherence to candidate quality measures for muscle invasive bladder cancer vary by hospital type?

SAN DIEGO, CA USA (UroToday.com) - Emerging pay-for-performance reimbursement mechanisms are directed at improving delivery of high-quality, valued-based care while reducing unnecessary utilization and expenditures.

A lack of level one evidence has limited development of rigorous metrics to reliably measure quality for patients undergoing surgical treatment of muscle invasive bladder cancer (MIBC), and current proposed performance measures are largely based on expert opinion. Our aim was to assess trends in performance of candidate quality measures in patients undergoing RC for MIBC, by hospital type, using a large national tumor registry.

 

poster Corcoran AUA2013 temple MCS final thumb

Presented by Anthony T. Corcoran,1 Elizabeth Handorf,2 Dan Canter,3 Justin E. Bekelman,4 Simon P Kim,5 Robert G. Uzzo,1 Alexander Kutikov,1 and Marc C. Smaldone1 at the American Urological Association (AUA) Annual Meeting - May 4 - 8, 2013 - San Diego Convention Center - San Diego, California USA

Division of Urologic Oncology,1 Biostatistics & Bioinformatics Facility,2 Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA; Department of Urology,3 Emory University School of Medicine, Atlanta, GA; Department of Radiation Oncology,4 University of Pennsylvania School of Medicine, Philadelphia, PA; Department of Urology,5 Mayo Clinic, Rochester, MN



aua



View Full AUA 2013 Coverage



 

 

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe